Skip to content
★ Sign in to follow
RA

Robert A. Copeland

CEO
Epizyme, Inc.
Total declarations
75
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (47 ops.)
€6.2M

Latest filing published 07 Jun 2017 for Epizyme, Inc., €7,852.

Filing timeline

BuySale
Robert A. Copeland

Insider track record

Disclosed buys
0
Disclosed sells
47
Signal history

Robert A. Copeland: trading record in brief

Robert A. Copeland appears in our data through filings on Epizyme, Inc. shares, published by SEC (Form 4). We count 75 filings; the first trade dates from 2 December 2013 and the latest from 6 June 2017.

Sales make up the whole of the open-market record (47 sales, €6.2M). Other entries cover 28 option exercises. 2017 to date brings no purchases and 4 sales.

The latest filing, published on 7 June 2017, reports an option exercise of €7,852 in Epizyme, Inc. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Robert A. Copeland

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations74 total
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    8,850 USD11SEC
    2,500 shares@ US$3.541.8% of flowCommons Stock, par value $0.0001SEC:0001209191-17-038262:0
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    33,625 USD24SEC
    2,500 shares@ US$13.456.9% of flowCommons Stock, par value $0.0001SEC:0001209191-17-038262:1
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    17,700 USD11SEC
    5,000 shares@ US$3.543.7% of flowCommons Stock, par value $0.0001SEC:0001209191-17-029545:0
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    87,200 USD13SEC
    5,000 shares@ US$17.4418.3% of flowCommons Stock, par value $0.0001SEC:0001209191-17-029545:1
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    4,380 USD11SEC
    2,000 shares@ US$2.190.9% of flowCommons Stock, par value $0.0001SEC:0001209191-17-025793:0
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    10,620 USD11SEC
    3,000 shares@ US$3.542.3% of flowCommons Stock, par value $0.0001SEC:0001209191-17-025793:1
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    40,900 USD24SEC
    2,500 shares@ US$16.368.8% of flowCommons Stock, par value $0.0001SEC:0001209191-17-025793:2
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    8,760 USD11SEC
    4,000 shares@ US$2.191.8% of flowCommonStock, par value $0.0001SEC:0001209191-16-135122:0
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    41,480 USD24SEC
    4,000 shares@ US$10.378.5% of flowCommonStock, par value $0.0001SEC:0001209191-16-135122:1
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    8,760 USD11SEC
    4,000 shares@ US$2.191.8% of flowCommon Stock, par value $0.0001SEC:0001209191-16-131945:0
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    40,120 USD24SEC
    4,000 shares@ US$10.038.3% of flowCommon Stock, par value $0.0001SEC:0001209191-16-131945:1
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    111,645 USD13SEC
    31,538 shares@ US$3.5422.9% of flowCommon Stock, par value $0.0001SEC:0001209191-16-124962:0
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    0SEC
    292 sharesCommon Stock, par value $0.0001SEC:0001209191-16-088021:0
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    0SEC
    3,893 sharesCommon Stock, par value $0.0001SEC:0001209191-16-088021:2
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    60,635 USD19SEC
    3,893 shares@ US$15.575493.0% of flowCommon Stock, par value $0.0001SEC:0001209191-16-088021:3
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    4,548 USD12SEC
    292 shares@ US$15.57547.0% of flowCommon Stock, par value $0.0001SEC:0001209191-16-088021:1
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    1,009 USD0SEC
    1,682 shares@ US$0.60Common Stock, par value $0.0001 per shareSEC:0001209191-15-084097:0
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    23,248 USD0SEC
    1,682 shares@ US$13.8215Common Stock, par value $0.0001 per shareSEC:0001209191-15-084097:1
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    5,482 USD0SEC
    2,503 shares@ US$2.19Common Stock, par value $0.0001 per shareSEC:0001209191-15-084097:2
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    34,595 USD0SEC
    2,503 shares@ US$13.8215Common stock, par value $0.0001 per shareSEC:0001209191-15-084097:3
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    2,511 USD0SEC
    4,185 shares@ US$0.60Common Stock, par value $0.0001 per shareSEC:0001209191-15-079292:0
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    68,059 USD0SEC
    4,185 shares@ US$16.2626Common Stock, par value $0.0001 per shareSEC:0001209191-15-079292:1
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    2,511 USD0SEC
    4,185 shares@ US$0.60Common Stock, par value $0.0001 per shareSEC:0001209191-15-074017:0
  • ▼
    President of Research and CSOExecutivesEpizyme, Inc.
    60,380 USD0SEC
    4,185 shares@ US$14.4277Common Stock, part value $0.0001 per shareSEC:0001209191-15-074017:1
  • ◇
    President of Research and CSOExecutivesEpizyme, Inc.
    2,511 USD0SEC
    4,185 shares@ US$0.60Common Stock, par value $0.0001 per shareSEC:0001209191-15-070239:0

25 of 74 declarations